Developing next generation treatments to preserve vision for patients with diseases affecting the back of the eye

First in class pharmacological solution for treatment of symptomatic vitreomacular adhesion and vitreomacular traction


JETREA® (ocriplasmin) is the first and only pharmacological treatment indicated for symptomatic vitreomacular adhesion and vitreomacular traction (sVMA/ VMT). Ocriplasmin is a truncated form of human plasmin. It is a small molecule designed for use in the eye that cleaves fibronectin, laminin and collagen, three major components of the vitreoretinal interface. First introduced in 2013, over 30,000 patients have been treated with Jetrea so far.

Oxurion owns the global commercial rights to this product and will capitalize on the global opportunities and unlocked potential to commercialize Jetrea further on a global scale, and to the benefit of the patients.

Our strong focus enables us to truly make a difference in bringing value to end users and change patients' lives

- Vinciane Vangeersdaele, Chief Commercial Officer of Oxurion

Read full interview

Commercial business unit

Oxurion has a full operational business unit to meet all requirements for commercializing Jetrea and other products on a global scale. The commercial team works closely together on all aspects: regulatory, supply chain, legal and commercial. Vinciane Vangeersdaele leads this team as Chief Commercial Officer. 

Contact us